LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "exon mutations" as a keyword



Longitudinal analysis of serum interleukin‐18 in patients with familial Mediterranean fever carrying MEFV mutations in exon 10

Sign Up to like & get
recommendations! Published in 2018 at "Cytokine"

DOI: 10.1016/j.cyto.2017.10.007

Abstract: Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease caused by mutations in the MEFV gene. Mutations in exon 10 are associated with typical FMF phenotypes, and patients with exon 10 mutations have higher serum… read more here.

Keywords: mutations exon; familial mediterranean; exon mutations; serum ... See more keywords

Abstract 511: Neratinib monotherapy in advanced non-small cell lung cancer with EGFR exon 18 mutations in China

Sign Up to like & get
recommendations! Published in 2025 at "Cancer Research"

DOI: 10.1158/1538-7445.am2025-511

Abstract: In NSCLC patients, EGFR exon 18 mutations account for approximately 3-5% and are associated with a poor prognosis. In phase 2 SUMMIT global trial, 29 metastatic NSCLC patients with EGFR exon 18 mutations received neratinib… read more here.

Keywords: exon mutations; cancer; egfr exon; neratinib monotherapy ... See more keywords

Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.e20636

Abstract: e20636Background: Activation of MET oncogene as the result of amplification or activation MET exon 14 mutations represents an emerging molecular target for non-small cell lung cancer (NSCLC) treatm... read more here.

Keywords: exon mutations; lung cancer; cell lung; non small ... See more keywords

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.3_suppl.tps767

Abstract: TPS767 Background: Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal sarcoma with approximately 80% of cases driven by KIT mutations. Most patients (pts) with advanced GIST experience disease progression following first-line treatment with imatinib… read more here.

Keywords: exon mutations; kit; advanced gist; ripretinib sunitinib ... See more keywords

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation

Sign Up to like & get
recommendations! Published in 2017 at "Internal Medicine"

DOI: 10.2169/internalmedicine.56.7871

Abstract: Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F,… read more here.

Keywords: jak1 inhibitor; polycythemia vera; exon mutations; myelofibrosis ... See more keywords

Prognostic Value of KRAS Exon-specific Mutations in Patients With Colorectal Cancer

Sign Up to like & get
recommendations! Published in 2023 at "AntiCancer Research"

DOI: 10.21873/anticanres.16306

Abstract: Background/Aim: The clinical significance of many RAS-family mutations in colorectal cancer (CRC) remains unclear. The purpose of this study was to investigate the relationship of RAS mutations on an exon basis (i.e., mutations in KRAS… read more here.

Keywords: ras mutations; exon mutations; colorectal cancer; kras exon ... See more keywords

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Sign Up to like & get
recommendations! Published in 2021 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2021.637420

Abstract: Background The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a… read more here.

Keywords: response; exon mutations; therapeutic cancer; vaccination ... See more keywords